Regulus Therapeutics IncFind Ratings Reports
REGULUS THERAPEUTICS INC's gross profit margin for the first quarter of its fiscal year 2016 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry. REGULUS THERAPEUTICS INC is extremely liquid. Currently, the Quick Ratio is 9.63 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 26.96% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY16||Q1 FY15|
|Net Sales ($mil)||0.49||4.2|
|Net Income ($mil)||-21.21||-14.49|
|Balance Sheet||Q1 FY16||Q1 FY15|
|Cash & Equiv. ($mil)||106.02||148.79|
|Total Assets ($mil)||128.14||164.85|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q1 FY16||Q1 FY15|
|Gross Profit Margin||-4286.09||-297.07|
|Return on Assets||-48.75||-35.44|
|Return on Equity||-58.25||-39.79|
|Debt||Q1 FY16||Q1 FY15|
|Share Data||Q1 FY16||Q1 FY15|
|Shares outstanding (mil)||52.78||50.76|
|Div / share||0.0||0.0|
|Book value / share||2.03||2.89|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||895196.0||920667.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 1.68 indicates a discount versus the S&P 500 average of 2.81 and a significant discount versus the industry average of 11.16. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, REGULUS THERAPEUTICS INC proves to trade at a discount to investment alternatives within the industry.
|RGLS NM||Peers 40.39||RGLS NM||Peers 21.72|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
RGLS's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
RGLS's P/CF is negative making the measure meaningless.
|RGLS NM||Peers 122.62||RGLS NA||Peers 1.15|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
RGLS's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|RGLS 1.68||Peers 11.16||RGLS 8.40||Peers -19.12|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
RGLS is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
RGLS is expected to have an earnings growth rate that significantly exceeds its peers.
|RGLS 10.59||Peers 425.82||RGLS 66.51||Peers 40.81|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
RGLS is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
RGLS has a sales growth rate that significantly exceeds its peers.